Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors
- Authors:
- Hye-Rim Park
- Youn-Wha Kim
- Woon Won Jung
- Hyun Sook Kim
- K. K. Unni
- Yong-Koo Park
- Published online on: March 1, 2004 https://doi.org/10.3892/ijo.24.3.575
- Pages: 575-580
Metrics:
Total Views:
0
(Spandidos Publications:
| PMC Statistics:
)
Total PDF Downloads:
0
(Spandidos Publications:
| PMC Statistics:
)
Abstract
The expression of HER-2/neu has been proposed to be a prognostic indicator in osteosarcoma. To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. We used real-time PCR (LightCycler) assay to quantify the HER-2/neu gene status. The crossing point of HER-2 in normal control bone was 27.77. The crossing points of HER-2 in conventional, mesenchymal, and clear cell chondrosarcomas were 28.48±1.79, 27.74±3.02, 28.57±1.54, respectively. In conclusion, the amplification and overexpression of the HER-2/neu oncogene is absent or at least very rare in malignant cartilaginous tumors. The level of expression of HER-2/neu was similar in all cartilaginous tumor types.
